Read The Lupus Book: A Guide for Patients and Their Families, Third Edition Online
Authors: Daniel J. Wallace
proprionic acid derivatives,
209
nonsteroidal anti-inflammatories,
211;
and
prostaglandin,
148, 209, 264
pregnancy,
247;
and red blood cells,
153;
protein-losing enteropathy,
138
related diseases,
148–49;
renal vein
proteinuria,
146
thrombosis,
149;
specialized treatments,
232–
prothrombin activator complex,
163
33;
and steroids,
223;
treating,
149–50;
and prothrombin time (PT),
66
urogenital system,
145
proton-pump inhibitors,
137, 212, 224
research on lupus: ACR standards,
5–6;
animal
protozoans,
237
research,
32–33;
bimodal survival curve,
psychiatric disorders,
116, 117, 173
259–60;
economic impact of lupus,
252;
psychology,
192, 203
epidemiology of lupus,
256;
future,
261–66;
pulmonary angiograms,
87
on health care delivery,
256;
importance of,
pulmonary edema,
98
3–4;
incidence and prevalence,
11–13;
new
pulmonary emboli,
91–92, 161
drugs,
261–63;
and pregnancy,
249;
research
pulmonary hemorrhages,
92
deficits,
4;
statistics,
11;
survival studies,
pulmonary hypertension.
See
hypertension
pulse oximetry,
86–87
reticuloendothelial system (RES),
157
pulse steroids,
221–22
retina,
122
purpura,
70, 75–76, 157
retinoids,
231
review of systems,
59–61
quality of life,
263
rheumatic diseases,
22,
174–75.
See also
quinacrine,
215, 218, 232
rheumatoid arthritis
quinidine,
53
rheumatoid arthritis: antibody response,
31;
quinine,
214
and anti-RNP,
29;
association with lupus,
7;
complications,
90;
distinguishing from
race and lupus,
11, 13, 153, 256
lupus,
174;
genetic factors,
42;
and
radiation therapy,
46.
See also
chemotherapy
inflammation,
78, 175;
and lupus
raloxifene,
241
misdiagnosis,
12;
prevalence,
173
rapamycin,
264
rheumatoid factor,
31, 68
rapeseed oil,
45
rheumatology,
4, 59,
62,
257
rashes,
9, 70, 73
rhupus,
174
Raynaud’s phenomenon: association with
ribonucleic acid (RNA),
29
lupus,
6;
as autoimmune disease,
175;
and
rights of lupus patients,
196
biofeedback,
204;
and cutaneous lupus,
70;
rimantadine,
239
described,
74–75;
and headaches,
110;
and
risedronate,
241
nicotine,
194;
prevalence,
173;
symptoms,
Ropes, Marian,
9–10, 207
rosacea,
73
reagin,
159
Rose Bengal staining,
125
rectum,
134
rosemary,
190
red blood cells (erythrocytes),
17,
19, 21,
30,
Ro (SSA) antibodies,
244, 247
65.
See also
anemia
RPR screen,
68
reflex panel,
66
rue,
190
reflux disease,
133, 135
refractory skin disease,
264
sacroiliac joints,
82
regional ileitis,
137
St. John’s Wort,
186,
190
regional myofascial syndrome,
177
sairei-to,
190
Index
[289]
salicylates,
208,
209.
See also
aspirin
Social Security Disability,
252–53, 253–54
salivary glands,
125
sodium salicylates,
208
sarcoidosis,
175
sodium sucralfate,
137
sassafras,
190
soft tissue,
78–82
Schirmer’s test,
125
sore throat,
133
scleroderma: and anti-RNP,
29;
association
Southeimer, Rick,
184
with lupus,
6, 7;
and calcinosis,
81;
spastic colitis,
136
chemical factors,
44–45;
complications,
90;
specialists,
257
diagnosing,
4;
distinguishing from lupus,
spinal fluid,
107, 119
174;
and inflammation,
175;
prevalence,
173;
spleen,
156, 157–58
supplements for,
205
statistics on lupus,
11.
See also
research on
scotomas,
218
lupus
second opinions,
196
stem cell therapy,
265–66
seizures,
105
sterility,
225, 243–44
selective cox-2 antagonists,
209,
212
steroids: adverse reactions to,
168, 202, 204–5,
self-help,
195, 197, 203
223–25;
and antimalarials,
216;
appearance
senna,
190
issues,
196;
blood problems,
157;
dosages,
serotonin boosters,
179, 193, 203
222–23;
and drug-induced lupus,
55;
and
Serra, Junipero,
259
fevers,
63;
future of,
261;
and immune
serum protein electrophoresis,
68
response,
23;
and infections,
238;
and life
sex and lupus,
35, 131–32, 202–3.
See also
expectancy,
255;
and lymphocytes,
233–34;
gender and lupus
nonfluorinated,
220;
preparations of,
221
;
shoulders,
81
and psychosis,
116;
variety of,
220–22;
shrinking lung syndrome,
93
withdrawal,
224
sickle cell anemia,
153
stomach,
134
sight problems,
121–23.
See also
eyes
streptococcus,
99–100
signs,
61.
See also
diagnosis and assessment
stress,
198, 199–200, 222–23
silica / silicone,
44
strokes,
106, 117, 161, 194, 250
Simon, Lee,
262
Strongyloides,
237
single-positron-emission computed tomography
ST segments,
96
(SPECT),
119
subacute bacterial endocarditis,
100
sinus infections,
123
subacute cutaneous lupus erythematosus
Sioux Indians,
13
(SCLE),
41, 70, 71–72, 231.
See also
6-mercaptopurine,
226,
228
discoid lupus erythematosus (DLE)
Sjo¨gren’s syndrome: antimalarials for,
215,
substance abuse,
173
216;
and autoantibodies,
30;
as autoimmune
suldinac,
210
disease,
175;
blood tests for,
67;
and blood
sulfa antibiotics,
240
thickness,
109;
complications,
90;
described,
sulfa derivatives,
50, 206, 258
124–26;
and eye problems,
121;
genetic
sulfasalazine,
50
factors,
41;
and lupus misdiagnosis,
12;
in
sulfonamide-based antibiotics,
50
mothers,
166;
and renal function,
149;
and
sun sensitivity: and antibiotics,
240;
anti-DNA
sexual dysfunction,
132;
and thyroid,
130;
formation,
46;
and antimalarials,
215;
and
and vaginal dryness,
202
drug-induced lupus,
52;
fear of,
197;
and
skeletal structure.
See
musculoskeletal system
immune suppressive therapies,
227;
and
skin,
69–77;
atrophy,
70;
criteria,
5,
7
;
NSAIDs,
210;
polymorphous light eruption,
diagnosis,
61, 62;
disorders,
76, 215;
malar
73;
preventive measures,
183–84;
and
rash,
9, 70, 73;
pigmentation,
73;
refractory
retinoids,
231;
skin damage,
69;
sunscreens
skin disease,
264;
and steroids,
223.
See
listed,
185
also
discoid lupus erythematosus (DLE)
supplements,
45–46, 205, 241,
241
sleeping problems,
111, 192–93, 223
slow acetylators,
44, 52
surgery,
181
small intestine,
134
susceptibility to lupus,
13
smoking,
193–94
Swan-Ganz catheter,
93
social issues of lupus,
168
symptoms.
See
diagnosis and assessment
[290]
Index
synovial cysts,
80
tissue malignancies,
173
synovial fluid,
80
T lymphocytes (T cells): abnormalities,
36;
synovium,
78–80,
79
and antibody production,
24,
24
;
and
syphilis,
68, 159, 162–63, 172
biologics,
266;
formation of,
19
;
growth
Systematic Lupus Erythematosus Self-Help
factor,
25;
and immune response,
18–20;
(SLESH) course,
195, 197
Systemic Lupus Activity Measure (SLAM),
tobacco use,
193–94
tolerance, loss of,
38
Systemic Lupus Erythematosus Disease
tolmetin,
210
Activity Index (SLEDAI),
262
topical anti-inflammatories,
212.
See also
systemic lupus erythematosus (SLE).
See
nonsteroidal anti-inflammatory drugs
specific topics such as
diagnosis and
(NSAIDs)
assessment, treatment,
etc.
total lymphoid irradiation (TLI),
234
Systemic Lupus International Coordinating
transcendental meditation,
204
Committee (SLICC),
257
transforming growth factor (TGF),
22,
155
transfusions,
154, 156
tachycardia,
95–96
transient ischemic attacks (TIAs),
109
tacrolimus,
227,
228,
264
transmission of lupus,
47
T’ai chi,
204
transplant anti-rejection drugs,
228
tartrazines,
44, 250
transplants,
233, 243, 260
tea tree oil,
190
transudates,
88, 138
teenagers.
See
adolescents with lupus
trauma associated with lupus,
199–200
teeth,
100, 123–24, 238
treatments for lupus: cognitive therapy,
203–4,
temperature readings,
63
258;
future of,
261–66;
immune ablative
temporomandibular joint (TMJ),
80–81, 123–
therapy,
265–66;
infections,
238;
other
options,
230–35;
proactive strategies,
257–
tender points,
176,
177
58;
response measures,
262–63;
stem cell
tendons,
79,
80
therapy,
265–66;
variables,
256.
See also
testosterone,
127, 230
chemotherapy; therapeutic approaches to
tests for lupus.
See
diagnosis and assessment
lupus;
specific drugs
tetracyclines,
50
triamcinolone,
221,
222, 245
thalidomide,
232
tricyclic antidepressants,
179, 193, 203
therapeutic approaches to lupus: categories,
trigger fingers,
80, 81
181;
cognitive therapy,
203–4, 258;
future
Tsao, Betty,
41
of,
261–66;
immune ablative therapy,
265–
tubular dysfunction,
149